- Home
- RIGL vs GMGI Comparison
RIGL vs GMGI Comparison
Compare RIGL & GMGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- GMGI
- Stock Information
- Founded
- RIGL 1996
- GMGI 2008
- Country
- RIGL United States
- GMGI United States
- Employees
- RIGL N/A
- GMGI N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- GMGI Computer Software: Prepackaged Software
- Sector
- RIGL Health Care
- GMGI Technology
- Exchange
- RIGL Nasdaq
- GMGI Nasdaq
- Market Cap
- RIGL 334.5M
- GMGI 280.0M
- IPO Year
- RIGL 2000
- GMGI N/A
- Fundamental
- Price
- RIGL $18.28
- GMGI $1.70
- Analyst Decision
- RIGL Buy
- GMGI Strong Buy
- Analyst Count
- RIGL 5
- GMGI 1
- Target Price
- RIGL $36.40
- GMGI $4.00
- AVG Volume (30 Days)
- RIGL 205.1K
- GMGI 137.2K
- Earning Date
- RIGL 05-06-2025
- GMGI 05-08-2025
- Dividend Yield
- RIGL N/A
- GMGI N/A
- EPS Growth
- RIGL N/A
- GMGI N/A
- EPS
- RIGL 2.08
- GMGI N/A
- Revenue
- RIGL $203,077,000.00
- GMGI $168,987,998.00
- Revenue This Year
- RIGL $24.45
- GMGI $34.49
- Revenue Next Year
- RIGL $7.23
- GMGI $12.92
- P/E Ratio
- RIGL $8.77
- GMGI N/A
- Revenue Growth
- RIGL 70.16
- GMGI 77.72
- 52 Week Low
- RIGL $7.48
- GMGI $1.70
- 52 Week High
- RIGL $29.82
- GMGI $6.27
- Technical
- Relative Strength Index (RSI)
- RIGL 47.44
- GMGI 36.11
- Support Level
- RIGL $17.65
- GMGI $1.63
- Resistance Level
- RIGL $19.75
- GMGI $1.96
- Average True Range (ATR)
- RIGL 1.46
- GMGI 0.11
- MACD
- RIGL -0.02
- GMGI -0.03
- Stochastic Oscillator
- RIGL 16.39
- GMGI 14.89
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About GMGI Golden Matrix Group Inc.
Golden Matrix Group Inc is an established gaming technology company. The company develops and owns online gaming IP and builds configurable and scalable white-label social gaming platforms for its international customers. The company operates in three reportable segments; MeridianBet Group, GMAG, RKings & CFAC. The MeridianBet Group segment earns majority revenue. The company operates in UK, Europe, Asia Pacific, Central and South America, Australia and Africa. It offers configurable and scalable iGaming platforms and operate some of the industry's iconic brands, including MexPlay, GM-AG, and others.